Literature DB >> 3874606

Cross-sectional study of rheumatoid arthritis treatment in a university hospital.

W T Friesen, Y A Hekster, L B van de Putte, F W Gribnau.   

Abstract

Drug prescribing patterns for the management of inpatients and outpatients with rheumatoid arthritis (RA) were investigated. The population of patients resembled published epidemiological descriptions of RA patients with respect to age and sex distribution. Multiple drug therapy was common in the treatment of both hospitalised and clinic patients. 90% of all patients with RA received non-steroidal anti-inflammatory drug (NSAID) therapy, indomethacin and naproxen being the two most frequently prescribed NSAIDs for both in- and outpatients. The vast majority of inpatients (85%) and outpatients (79%) received slow-acting antirheumatic drug (SAARD) treatment. 13% of hospitalised patients received H2-antagonist drugs in addition to their NSAIDs. A high proportion of inpatients (46%) received oral corticosteroids in the management of their rheumatoid arthritis, while only 15% of clinic patients were prescribed corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874606      PMCID: PMC1001655          DOI: 10.1136/ard.44.6.372

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

Review 1.  Do drugs change the course of rheumatoid arthritis?

Authors:  V Wright; R Amos
Journal:  Br Med J       Date:  1980-04-05

Review 2.  Current status of disease-modifying drugs in progressive rheumatoid arthritis.

Authors:  J D O'Duffy; H S Luthra
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  A pharmacist's audit of antirheumatic drugs.

Authors:  L Takavarasha; D L Scott; T J Constable
Journal:  Rheumatol Rehabil       Date:  1982-11

Review 4.  Adult and juvenile rheumatoid arthritis: current epidemiologic concepts.

Authors:  M C Hochberg
Journal:  Epidemiol Rev       Date:  1981       Impact factor: 6.222

5.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality.

Authors:  A Linos; J W Worthington; W M O'Fallon; L T Kurland
Journal:  Am J Epidemiol       Date:  1980-01       Impact factor: 4.897

6.  The impact of chronic disease: a sociomedical profile of rheumatoid arthritis.

Authors:  R F Meenan; E H Yelin; M Nevitt; W V Epstein
Journal:  Arthritis Rheum       Date:  1981-03

7.  Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis.

Authors:  J J Rasker; J A Cosh
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

8.  The long-term effects of treating rheumatoid arthritis.

Authors:  D L Scott; B L Coulton; J H Chapman; P A Bacon; A J Popert
Journal:  J R Coll Physicians Lond       Date:  1983-01
  8 in total
  5 in total

1.  Corticosteroids in rheumatoid arthritis: is a trial of their 'disease modifying' potential feasible?

Authors:  M A Byron; J R Kirwan
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

2.  [Do patients with active chronic polyarthritis get "basic therapy"?].

Authors:  H H Raspe; A Wasmus
Journal:  Soz Praventivmed       Date:  1988

3.  Rational use of analgesics in the treatment of the rheumatic disorders.

Authors:  F D Hart
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

4.  Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis.

Authors:  W Grassi; R De Angelis; C Cervini
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  Polypharmacy in Middle-European Rheumatoid Arthritis-Patients: A Retrospective Longitudinal Cohort Analysis With Systematic Literature Review.

Authors:  Jacqueline Désirée Jack; Rick McCutchan; Sarah Maier; Michael Schirmer
Journal:  Front Med (Lausanne)       Date:  2020-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.